다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
한국임상약학회지 = Korean journal of clinical pharmacy, v.32 no.1, 2022년, pp.13 - 19
최하은 (중앙대학교 약학대학) , 이지원 (중앙대학교 약학대학) , 제남경 (부산대학교 약학대학) , 정경혜 (중앙대학교 약학대학)
AI-Helper
Background: The use of combination therapy and fixed-dose combination therapy is increasing for the treatment of type 2 diabetes. Sodium glucose cotransporter-2 inhibitor (SGLT2i) is a drug class used in combination with metformin. Methods: Type 2 diabetes patients on SGLT2i/metformin combination th...
Korean Statistical Infromation Service. Diabetes: ≥30 years 2021. Available from https://kosis.kr/statHtml/statHtml.do?orgId177&tblIdDT_11702_N102&conn_pathI2&languageen. Accessed September 23, 2021.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-53.
Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378(9785):31-40.
Korean diabetes association. Clinical practice guidelines for diabetes 2021. Available from https://www.diabetes.or.kr/pro/publish/guide.php?modelist. Accessed January 07, 2022.
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2021. Diabetes care 2021;44(Suppl 1):S111-S124.
Ko SH, Kim DJ, Park JH, et al. Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002-2013: Nationwide population-based cohort study. Medicine (Baltimore) 2016;95(27):e4018.
Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action. J Diabetes Investig 2014;5(3):265-75.
Ministry of Food and Drug Safety. Medicines integrated information system. Available from https://nedrug.mfds.go.kr/searchDrug. Accessed January 07, 2022.
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2019. Diabetes care 2019;42(Suppl. 1):S90-S102.
Huang ES, Karter AJ, Danielson KK, Warton EM, Ahmed AT. The association between the number of prescription medications and incident falls in a multi-ethnic population of adult type-2 diabetes patients: the diabetes and aging study. J Gen Intern Med 2010;25(2):141-6.
Bluher M, Kurz I, Dannenmaier S, Dworak M. Pill burden in patients with type 2 diabetes in Germany: Subanalysis from the prospective, noninterventional PROVIL study. Clin Diabetes 2015;33(2):55-61.
Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med 2002;19(4):279-84.
Baumgartner A, Drame K, Geutjens S, Airaksinen M. Does the polypill improve patient adherence compared to its individual formulations? A systematic review. Pharmaceutics 2020;12(2):190.
Bell DS. Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab 2013;15(4):291-300.
Zonszein J, Groop PH. Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease. Diabetes Ther 2016;7(4):621-39.
Lingvay I, Nadine Beetz N, Sennewald R, et al. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes. Postgrad Med 2020;132(4):337-45.
Han S, Iglay K, Davies MJ, Zhang Q, Radican L. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Curr Med Res Opin 2012;28(6):969-77.
Blonde L, Wogen J, Kreilick C, Seymour AA. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 2003;5(6):424-31.
HU J, Zou P, Zhang S, Zhou M, Tan X. Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes. Expert Opin Pharmacother 2016;17(18):2471-7.
Benford M, Milligan G, Pike J, Anderson P, Piercy J, Fermer S. Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. Adv Ther 2012;29(1):26-40.
Kim J, Park S, Kim H, Je NK. National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus. Eur J Clin Pharmacol 2019;75(12):1723-30.
Kaur KK, Allahbadia G, Singh M. Role of combination therapy with SGLT2 Inhibitor with metformin as initial treatment for type2 diabetes-advantages of oral fixed drug pill like empagliflozin/metformin in patients with cardiovascular and renal risk-A short communication. Arch Endocrinol Metab 2019;2(1):15-9.
Health Insurance Review and Assessment Service. Healthcare Bigdata Hub. Available from https://opendata.hira.or.kr/home.do. Accessed September 24, 2021.
Schipf S, Werner A, Tamayo T, et al. Regional differences in the prevalence of known Type 2 diabetes mellitus in 45-74 years old individuals: results from six population-based studies in Germany (DIAB-CORE Consortium). Diabet Med 2012;29(7):e88-95.
Valov V, Doneva M, Borisova AM, et al. Regional differences in diabetic patients' pharmacotherapy in Bulgaria. Eur Rev Med Pharmacol Sci 2014;18(10):1499-506.
Oh JA, Lee GM, Chung SY, Cho YS, Lee HJ. Utilization trends of proton pump inhibitors in South Korea: Analysis using 2016-2020 Healthcare Bigdata Hub by Health Insurance Review and Assessment Service. Yakhak Hoeji 2021;65(4):276-83.
Health Insurance Review and Assessment Service. 2019 Drug reimbursement adequacy evaluation result. Available from https://www.hira.or.kr/cms/open/04/04/12/2020_9.pdf. Accessed October 8, 2021.
Korean Statistical Infromation Service. Number of doctors employed in medical institutions per 1,000 population. Available from https://kosis.kr/statHtml/statHtml.do?orgId101&tblIdDT_1YL20981&conn_pathI2. Accessed October 8, 2021.
Frias JP. Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes. Expert Rev Endocrinol Metab 2019;14(2):75-83.
Hutchins V, Zhang B, Fleurence RL, Krishnarajah G, Graham J. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin 2011;27(6):1157-68.
Korean Pharmaceutical Information center. Available from https://www.health.kr/. Accessed December 25, 2021.
Park JH, Lee BK, Kim JY, Gwak HS. Comparisons of adherence, efficacy and price between sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in type 2 diabetes mellitus patients. Korean J Clin Pharm 2014;24(3):193-8.
Bohm AK, Schneider U, Aberle J, Stargardt T. Regimen simplification and medication adherence: Fixed-dose versus loose-dose combination therapy for type 2 diabetes. PLoS One 2021;16(5):e0250993.
Moriarty F, Bennett K, Fahey T. Fixed-dose combination antihypertensives and risk of medication errors. Heart 2019;105(3):204-9.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.